|
Galantamine
resources
|
|
|
|
|
|
DRUG INFO
Galantamine
Drug Name:
Galantamine
Indication: For the treatment of mild to moderate dementia of the Alzheimer's type.
Pharmacology: Galantamine is a parasympathomimetic, specifically, a reversible cholinesterase inhibitor. Galantamine is indicated for the treatment of mild to moderate dementia of the Alzheimer's type. Galantamine is postulated to exert its therapeutic effect by enhancing cholinergic function. This is accomplished by increasing the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase. If this proposed mechanism of action is correct, Galantamine's effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. There is no evidence that Galantamine alters the course of the underlying dementing process.
Mechanism Of Action: Galantamine's proposed mechanism of action involves the increase of the concentration of acetylcholine through reversible inhibition of its hydrolysis by acetylcholinesterase.
Drug Category: Nootropic Agents; Parasympathomimetics; Parasympathomimetics; ATC:N06DA04
Brand Names/Synonyms: Galantamin; Galantamine; Galanthamine; Galanthamine Base; Galanthamine Hydrobromide; Jilkon; Lycoremin; Lycoremine; Reminyl
Dosage Forms: CAPSULE, EXTENDED RELEASE
Absorption: Not Available
Interactions: Not Available
Chemical IUPAC Name: (4aS,6R,8aS)-4a,5,9,10,11,12-Hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepin-6-ol
Chemical Formula: C17H21NO3
Half Life: 7 hours
Drug Type: Approved Drug
# Accession No: APRD00206
CAS Registry Number: 357-70-0
|
|
|
|
|
|
Galantamine News
(When available)
Pond scum shows promise against Alzheimer's Jan 7, 2006
NZZ Online, The researchers led by Karl Gademann and Friedrich Jüttner said the compound's effects are comparable to galanthamine, a cholinesterase inhibitor already ...
Natural Compound From 'Pond Scum' Shows Potential Activity Against ... Dec 27, 2005
Science Daily (press release) The natural compound’s potency is comparable to galanthamine, a cholinesterase inhibitor already approved for the treatment of Alzheimer’s, the researchers ...
Alzheimer's battle turns to pond scum Dec 27, 2005
United Press International Technology. Its potency is comparable to galanthamine, a cholinesterase inhibitor used to treat Alzheimer's, the Swiss researchers said. ...
Pond scum yields potential weapon against Alzheimer's Dec 30, 2005
Baltimore Sun, The compound's potency is comparable to that of galanthamine, an inhibitor already approved as a treatment, the researchers say. ...
Dealing With Alzheimer's 16 Jan 2006
Saturday Evening Post, The drugs include cholinesterase inhibitors such as Aricept, a drug derived from black pepper, and Reminyl, made from daffodil bulbs. ...
My wife needs drug to fight illness Jan 9, 2006
Norwich Evening News, John Harvey, 85, cares for his wife Pamela, 83, who is in the early stages of the disease and takes Reminyl, one of the drugs that could be removed from the ...
Part D, as in dreadful Jan 4, 2006
New York Daily News, ...(Good for you, Mom.). "Okay," says the social worker, scanning the index. "The Razadyne [formerly Reminyl - how do you like that? ...
Alzheimer's victims 'may have to buy illicit drugs' Jan 10, 2006
Daily Mail - UK, The National Institute of Clinical Excellence is proposing a ban on three drugs - Aricept, Exelon and Reminyl - on the grounds that they are too expensive for ...
Treatment options for dementia increase Dec 26, 2005
Hagerstown Morning Herald, ...the brain work more efficiently. These medications go by the trade names Aricept, Reminyl and Exelon. A fourth medication, Namenda ...
Alzheimer's crisis alert Jan 3, 2006
Norwich Evening News, ...of years.". Drugs which could be withdrawn include Aricept, Reminyl and Exalon, which all cost the NHS about £2.50 a day. They are ...
More outrage over drugs row Jan 5, 2006
Norwich Evening News, Drugs which could be withdrawn include Aricept, Reminyl and Exalon, which are prescribed in the first instance to prevent the condition progressing. ...
Curbs on Alzheimer drugs to be reviewed Dec 19, 2005
Reuters.uk, The other medicines affected are Reminyl, from Johnson & Johnson and Shire Pharmaceuticals Group Plc, and Novartis AG's Exelon, both of which are used like ...
UK reviews controversial curbs on Alzheimer drugs Dec 19, 2005
Reuters The other medicines affected are Reminyl, from Johnson & Johnson (JNJ.N: Quote, Profile, Research) and Shire Pharmaceuticals Group Plc (SHP.L: Quote, Profile ...
Voyager Pharmaceutical Corporation Announces Progress in ... Dec 22, 2005
Drug Newswire (press release), ...who are 65 years or older with mild to moderate Alzheimer's Disease and who have been taking Aricept(R), Exelon(R), Razadyne(TM) (formerly Reminyl(R)) or Cognex ...
It’s all in the name Dec 28, 2005
Calcutta Telegraph, ...changed. As it happened when the diabetes drug Amaryl was confused with the Alzheimer’s medicine Reminyl, and one person died. ...
|
|
|
